logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Resistance To Proteasome Inhibitors In Cancer Molecular Mechanisms And Strategies To Overcome Resistance 1st Edition Q Ping Dou Eds

  • SKU: BELL-4930972
Resistance To Proteasome Inhibitors In Cancer Molecular Mechanisms And Strategies To Overcome Resistance 1st Edition Q Ping Dou Eds
$ 31.00 $ 45.00 (-31%)

4.8

94 reviews

Resistance To Proteasome Inhibitors In Cancer Molecular Mechanisms And Strategies To Overcome Resistance 1st Edition Q Ping Dou Eds instant download after payment.

Publisher: Springer International Publishing
File Extension: PDF
File size: 6.69 MB
Pages: 390
Author: Q. Ping Dou (eds.)
ISBN: 9783319067513, 9783319067520, 3319067516, 3319067524
Language: English
Year: 2014
Edition: 1

Product desciption

Resistance To Proteasome Inhibitors In Cancer Molecular Mechanisms And Strategies To Overcome Resistance 1st Edition Q Ping Dou Eds by Q. Ping Dou (eds.) 9783319067513, 9783319067520, 3319067516, 3319067524 instant download after payment.

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

Related Products